April 6, 2018 10:05 AM EDT
Deals

With a dead­line loom­ing, Take­da CEO We­ber woos an­a­lysts for sup­port of a Shire buy­out

John Carroll

Editor & Founder

Shares of Shire surged a bit on Thurs­day as in­vestors ab­sorbed a se­ries of an­a­lysts re­ports un­der­scor­ing Take­da CEO Christophe We­ber’s in­tent of pur­su­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times